North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. Safety Status Evaluation Report
Time：2019-03-27
|
From：
|
Views：348
|
Font Size：Default Big Large
|
Print
|
1. Safety evaluation project name: North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. Huari Factory (West Factory Area) Safety Status Evaluation Report
2. Introduction to the safety assessment project:
Huari Factory (West Factory District) (hereinafter referred to as Huari Factory) of North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. (hereinafter referred to as Huari Factory) was founded in October 1994. It is a Sino-foreign cooperative enterprise jointly funded by North China Pharmaceutical Group and Japan's Arysta Life Science. It forms a penicillin industry chain company with one-stop production of penicillin from raw materials to preparations. The factory name uses "North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd.", and consists of three large-scale production units directly under Huari Factory (East Factory District), Huari Factory (West Factory District), and Beiyuan Factory. Huari Factory was renamed North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd., and its factory location, products and original business have not changed. After the merger, there are 825 employees in the east and west factories of Huari Factory, of which the west factory covers an area of 44807m2.
According to the safety evaluation contract signed between Hebei Huafei Technology Consulting Co., Ltd. and North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd., the scope of this evaluation covers the site of the West Factory, the general layout, production equipment, storage facilities, public works and auxiliary facilities, and safety management.
The plant now produces procaine penicillin, benzathine penicillin, chlorazacillin sodium, and flucloxacillin sodium with penicillin potassium salt, 6APA, procaine hydrochloride, DBED, and o-chloroyl chloride as raw materials. The output is 365t/a, 30t/a, 30t/a, respectively, and the running time is about 7920h/a.
3. Safety evaluation project leader, technical leader, process control leader, evaluation report compiler, report auditor, safety evaluator, registered safety engineer, and technical expert involved in the evaluation:
Safety evaluation project leader: Xu Zhe
Technical person in charge: Cao Shuhua
Person in charge of process control: Wang Lin
Evaluation Report Compilers: Xu Zhe, Gao Weili, Sun Guang, Yang Jiangming
Report Reviewer: Zhou Junhong
4. List of personnel, time, and main tasks to carry out safety evaluation work on site, and evaluation report time:
Safety evaluators, registered safety engineers, and technical experts involved in the evaluation: Xu Zhe, Sun Guang, Gao Weili
In September 2018, the "Safety Status Evaluation Report of North China Pharmaceutical Group Xiantai Pharmaceutical Co., Ltd. (Xichang District) " was completed.